Brewer Sports International (BSI), a multi-faceted global sports
advisory firm, and Amarantus BioScience Holdings, Inc.
(OTCQB:AMBS), a biotechnology company focused on the discovery and
development of novel diagnostics and therapeutics related to cell
cycle dysregulation, endoplasmic reticulum stress,
neurodegeneration and apoptosis, today announced a presentation by
Dr. Thomas Arendt, Professor at University of Leipzig, at the 3rd
Alzheimer's focused #C4CT (Coalition for Concussion Treatment)
Concussion Awareness Summit, powered by MDM Worldwide on Thursday,
July 31, 2014 at the United Nations in New York City, NY. Dr.
Arendt will summarize his scientific hypotheses regarding the
evolutional context of Alzheimer's disease, and an emerging
therapeutic target in a 30 minute presentation in the afternoon
session.
"I am pleased to accept the organizers' offer to present at
#C4CT," said Dr. Arendt. "After being the first to identify the
scientific principles underpinning Amarantus' diagnostic blood test
LymPro, I have continued my research into Alzheimer's disease with
a strong focus on human tissue evaluation from Alzheimer's
patients. I believe there is a need to take a much broader
perspective in thinking about Alzheimer's, and I am pleased to have
this unique forum to share my perspective with the world."
Dr. Thomas Arendt is Professor of Neuroscience and runs the Paul
Flechsig Institute of Brain Research which is a Research Institute
of Leipzig University with about 50 staff members. He is also the
Director of the Alzheimer Centre Leipzig and Director of the
Interdisciplinary Centre for Clinical Research Leipzig. He has over
30 years of experience in R&D of therapeutic and diagnostic
strategies of neurodegenerative disorders and has made several
seminal contributions to therapeutic concepts of Alzheimer´s
disease, including stem cell therapy and modulating tumor
suppressor genes. He has published work in top-ranked journals,
including Cell, Nature, J.Cell Biol., J. Neurosci., and holds
several patents for CNS diagnostics and treatment with some of them
out-licensed to biotech companies in the United States. Over the
last 30 years, his research has continuously been funded by the
German Research Foundation, German Federal Ministry for Education
and Research, European Commission and others. In the early eighties
of the 20th century, he was involved in identifying the
degeneration of the cholinergic system in Alzheimer´s disease
laying the basis for todays´ only available treatments. He is one
of the pioneers of the "cell-cycle theory" of Alzheimer´s disease
which he developed further towards a diagnostic and therapeutic
concept.
The #C4CT Concussion Awareness Summit is being convened on July
31, 2014 to explore the potential link between TBI and Alzheimer's
disease. A diverse working group of clinicians, medical
researchers, policy makers, international diplomats, athletes,
celebrities, and philanthropic organizations will be assembled to
raise awareness, advance clinical research, and develop public
policy in order to address this major unmet medical need and public
health issue.
To register or for additional information, please visit
www.c4ctsummit.com. For further event questions, please contact
Lindsay Lommel at lindsay.lommel@thebrewergroup.com. For
sponsorship information please visit:
http://www.c4ctsummit.com/sponsorship-opportunities/.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company
developing treatments and diagnostics for diseases associated with
neurodegeneration and protein misfolding-related apoptosis. AMBS
has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready
indication for Parkinson's Levodopa induced dyskinesia and Adult
ADHD. AMBS has an exclusive worldwide license to the Lymphocyte
Proliferation test ("LymPro Test(R)") for Alzheimer's disease and
owns the intellectual property rights to a therapeutic protein
known as Mesencephalic-Astrocyte-derived Neurotrophic Factor
("MANF") and is developing MANF-based products as treatments for
brain disorders. AMBS also owns intellectual property for the
diagnosis of Parkinson's disease ("NuroPro") and the discovery of
neurotrophic factors ("PhenoGuard"). Amarantus operations are
located at Janssen Labs @QB3 in San Francisco, CA. For further
information please visit www.Amarantus.com, or connect with the
Company on Facebook, LinkedIn, Twitter and Google+.
About Brewer Sports International
Brewer Sports International (BSI) is a multi-faceted sports
advisory firm within The Brewer Group Companies with a focus on the
business of sports, wellness and media for professional athletes,
sports agencies, public and private corporations and various
partners including international organizations, governments and
NGOs. Jack Brewer, five-year National Football League (NFL) veteran
and former three-team captain, launched BSI in Minneapolis and
expanded to New York, Dallas, Miami, Beijing and Malawi. BSI offers
a unique financial services platform to professional athletes and
sports agencies, as well as high-net-worth individuals and
businesses related to professional sports. BSI takes pride in
enabling its clients to capitalize on the endless opportunities
presented through sport. For more information, please visit
www.brewersports.com or follow them on Facebook, Twitter and
LinkedIn.
About MDM Worldwide
MDM Worldwide Solutions, Inc. is a digital communications agency
that develops and manages online engagement strategies to connect
companies with their stakeholders. MDM specializes in working with
clients in the technology, healthcare and life sciences spaces.
MDM's vast industry knowledge, proprietary methodology, proven
track record and experienced leadership team enables them to create
and customize targeted digital marketing campaigns to fulfill all
of their clients' objectives. For more information, please visit
mdmworldwide.com or find them on Facebook, Twitter, Google+ and
LinkedIn.
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are
forward-looking statements. These forward-looking statements
generally are identified by the words "believes," "project,"
"expects," "anticipates," "estimates," "intends," "strategy,"
"plan," "may," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are based on current expectations and assumptions that are subject
to risks and uncertainties which may cause actual results to differ
materially from the forward-looking statements. Our ability to
predict results or the actual effect of future plans or strategies
is inherently uncertain. Factors which could have a material
adverse effect on our operations and future prospects on a
consolidated basis include, but are not limited to: changes in
economic conditions, legislative/regulatory changes, availability
of capital, interest rates, competition, and generally accepted
accounting principles. These risks and uncertainties should also be
considered in evaluating forward-looking statements and undue
reliance should not be placed on such statements.
CONTACT: Brewer Sports International:
Kristi Hofacker, Director of Interactive Marketing and Media
651.247.4460
kristi.hofacker@thebrewergroup.com
Amarantus Bioscience Holdings, Inc.:
Aimee Boutcher, Investor Relations
408.737.2734 x 101
ir@amarantus.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2023 to Apr 2024